Pfizer and Concert Pharmaceuticals are the two companies with the most advanced drugs for the indication of Alopecia Areata. Pfizer has press released results for their lead candidate PF-06651600 here Phase 2 Data in Alopecia Areata. The drug achieved a -33.6 reduction in SALT score at 24 weeks from a baseline of 88.1. Below are the percentages of reduction of SALT score points for both Pfizer drugs. PF-06651600 is the drug that the company will be taking forward into phase 3 clinical trials.
Table. Percentage of Patients with Better SALT Scores at Week 24 Weeks
Improvement in SALT ScorePF-06651600 Group %, PF-06700841 Group, %
In the Columbia University phase 2 clinical trial Ruxolitinib for Alopecia Areata, 20mg bid dosing achieved good results based on the percentage of SALT improvement from baseline. At this time we do not know what the maximum dose that the FDA will allow Concert to run in clinical trials, as it is currently testing 8mg. CTP-543 is the deuterated version of Ruxolitinib currently in phase 2 clinical trials for Alopecia Areata. Thank you for reading.
Table. Percentage of Patients with Better SALT Scores at Week 24 Weeks
Improvement in SALT ScorePF-06651600 Group %, PF-06700841 Group, %
30%
47.9
59.6
50%
37.5
48.9
75%
27.0
38.3
90%
25.0 31.9
100%
12.5 12.0In the Columbia University phase 2 clinical trial Ruxolitinib for Alopecia Areata, 20mg bid dosing achieved good results based on the percentage of SALT improvement from baseline. At this time we do not know what the maximum dose that the FDA will allow Concert to run in clinical trials, as it is currently testing 8mg. CTP-543 is the deuterated version of Ruxolitinib currently in phase 2 clinical trials for Alopecia Areata. Thank you for reading.
No comments:
Post a Comment